SANA Sana Biotechnology
- 8.350
- -0.280-3.24%
Sana Biotechnology News
Bank of America Securities Remains a Buy on Sana Biotechnology (SANA)
Sana Biotechnology Analyst Ratings
Buy Rating Affirmed for Sana Biotechnology Amidst Strong Clinical Progress and Solid Financials
Sana Biotechnology Analyst Ratings
Sana Biotechnology: Buy Rating Affirmed Amid Anticipation of Clinical Breakthroughs and Hypoimmune Platform Validation
Analysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA) and Sana Biotechnology (SANA)
Sana Biotechnology Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Masimo (MASI), Sana Biotechnology (SANA)
Buy Rating for Sana Biotechnology Amidst Promising Developments and Strong Financials
Buy Rating Affirmed on Sana Biotechnology Amid Promising ARDENT Trial Results for SC291 Therapy
H.C. Wainwright Keeps Their Hold Rating on Sana Biotechnology (SANA)
Buy Rating for Sana Biotechnology's Stock Backed by Promising Hypoimmune Platform and Anticipated Readouts
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (VCEL), Sana Biotechnology (SANA) and Lyra Therapeutics (LYRA)
Analysts Conflicted on These Healthcare Names: Sana Biotechnology (SANA), 23andMe Holding (ME) and Invitae (NVTA)
JMP Securities Maintains Market Outperform on Sana Biotechnology, Lowers Price Target to $8
Sana Biotechnology Analyst Ratings
Sana Biotechnology's Positive Outlook: A Buy Rating Based on Ex Vivo Cell Therapy Commitment and Potential Breakthroughs in CAR T Therapies
Samantha Semenkow Upholds Buy Rating for Sana Biotechnology Amid Positive Restructuring and Potential Data Validation
JMP Securities Initiates Coverage On Sana Biotechnology With Market Outperform Rating, Announces Price Target of $9
Sana Biotechnology Analyst Ratings
Analysis
Price Target
No Data
